Physician profile
Michael E Helm
NPI 1043461932
$1,363.88
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $19.91 · 2023: $403 · 2024: $941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,343.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $323.96 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $260.13 | 2023-2024 | Xifaxan, Trulance, Plenvu |
| Phathom Pharmaceuticals, INC. | $241.17 | 2023-2024 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $102.06 | 2023-2024 | Dupixent |
| Aimmune Therapeutics, INC. | $87.31 | 2024 | |
| Genzyme Corporation | $73.32 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.97 | 2023-2024 | Entyvio |
| Lilly USA, LLC | $38.33 | 2024 | Omvoh |
| Janssen Biotech, INC. | $33.33 | 2023-2024 | Stelara |
| Ardelyx, INC. | $31.43 | 2023 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $23.18 | 2023 | |
| Medtronic, INC. | $22.62 | 2024 | Gi Genius |
| Abbott Laboratories | $19.91 | 2021 | |
| Celgene Corporation | $18.31 | 2023 | Zeposia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.47 | 2024 | Cyltezo |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $13.38 | 2023 | Sucraid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Helm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.